Environmental Monitoring How to Satisfy the Regulator Presented by Tanja Varglien, July 2017 Slide 1 PharmOut 2017
Using Glisser You will be able to tap the download link at the end of each presentation. This will send you an email with a link to a PDF copy of the presentation slides. You cannot edit the slides, or view any presentation notes added to the original file. The live link to the presentation slides (via the glsr.it code) remains live until PharmOut deletes the presentation. Slide 2 PharmOut 2017
PIC/S Code of GMP Regulatory Requirements The PIC/S Guide to GMP requires that Clause 3.3 Lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the medicinal products during their manufacture or storage Clause 5.10 - Products and materials should be protected from microbial and other contamination. Annex 1 Clause 8 Clean rooms and clean air devices should be routinely monitored in operation and the monitoring locations based on a formal risk analysis study and the results obtained during the classification of rooms and/or clean air devices Slide 3 PharmOut 2017
PIC/S Code of GMP Regulatory Requirements (PE 009-13) Annex 3, Clause 19 Workstations and their environment should be monitored with respect to radioactivity, particulate and microbiological quality as established during performance qualification (PQ) Part II, Clause 18.15 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality of the environment and the frequency of monitoring should depend on the step in production and the production conditions (open, closed, or contained systems) Slide 4 PharmOut 2017
General Requirements for Viable Environmental Monitoring Annex 1 Clause 18 Where aseptic operations are performed monitoring should be frequent using methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates) Sampling methods used in operation should not interfere with zone protection Results from monitoring should be considered when reviewing batch documentation for finished product release Surfaces and personnel should be monitored after critical operations Slide 5 PharmOut 2017
General Requirements for Viable Environmental Monitoring Annex 1 Additional microbiological monitoring is also required outside production operations, e.g. after validation of systems, cleaning and sanitisation. Clause 19 - Recommended limits for microbiological monitoring of clean areas during operation Clause 20 - Appropriate alert and action limits should be set for the results of particulate and microbiological monitoring. If these limits are exceeded operating procedures should prescribe corrective actions Slide 6 PharmOut 2017
Viable Environmental Monitoring Environmental monitoring is a tool utilised to evaluate the effectiveness of controls on the manufacturing environment. These controls include: Layout of the facility Process and personnel flows HVAC design Monitoring and maintenance Facility and equipment cleaning and sanitization/disinfection programs Facility environmental monitoring data is used to assess the current and continued effectiveness of the cleaning and sanitisation agents and procedures. Slide 7 PharmOut 2017
Viable Environmental Monitoring Program The environmental monitoring program should be designed and implemented based on sound scientific principles The frequency, location and number of monitoring locations should be based on a formal risk assessment e.g. Product contact pathways, product exposure Personnel flows Hard to access or difficult to clean areas worse-case Monitoring locations should be defined and documented e.g. procedure, maps, photos The frequency and level of monitoring should be defined e.g. every shift, daily, weekly, monthly Slide 8 PharmOut 2017
Monitoring Methods A variety of monitoring methods may be utilised e.g. Passive air sampling e.g. settle plates Active air sampling e.g. Centifugal, filtration, STA Surface monitoring e.g. swabs, contact plates (RODAC) For settle plates, the maximum time settle plates can be exposed should be validated and defined. Plates can dessicate if left exposed for too long a period. Annex 15, Clause 9.3 Where microbial testing of surfaces in clean rooms is carried out, validation should be performed on the test method to confirm that sanitising agents do not influence the recovery of microorganisms Slide 9 PharmOut 2017
Monitoring Methods Procedures should describe how samples are taken and processed e.g. For swabbing, a 10cm x 10cm area is swabbed; rotate the swab during sampling. Sanitation of media into the filling room Slide 10 PharmOut 2017
Monitoring Media Clause 6.25 The in-use shelf life of microbiological media should be established, documented and scientifically justified. Clause 6.19 - Special attention should be given to the quality of laboratory reagents, volumetric glassware and solutions, reference standards and culture media. They should be prepared in accordance with written procedures. Clause 6.20 Laboratory reagents, solutions, reference standards and culture media should be marked with the preparation and opening date and the signature of the person who prepared them. The expiry date of reagents and culture media should be indicated on the label, together with storage conditions. Slide 11 PharmOut 2017
Monitoring Media Neutralizers should be added to media to inactivate surfaces treated with chemical disinfectants Are there procedures in place for the preparation, QC, release and storage of media? Is the media made in-house or purchased ready made? If made in-house, ensure the following records are available Control and traceability of starting materials Sterilization records Quality control records e.g. growth promotion, sterility Slide 12 PharmOut 2017
Monitoring Media If purchased ready made, ensure the following records are available Certificate of Analysis Results of QC testing (as applicable) Supplier qualification records (as applicable) Validated process (sanitation) for transferring media and equipment to aseptic filling rooms Slide 13 PharmOut 2017
Incubation conditions Manufacturers should select appropriate media and incubation regimes. For general (TSA) media, media is usually incubated at 30-35 C for 3 5 days For fungi, media is usually incubated at room temperature (20-25 C for 5 7 days) A combination regime may be appropriate Slide 14 PharmOut 2017
Monitoring Limits Action limits are generally based on any applicable regulatory requirements (Annex 1) Alert limits are generally driven by a review of historical data or commensurate with the activities being performed. If these limits are exceeded, procedures should prescribe corrective actions Slide 15 PharmOut 2017
Remedial Actions to be taken in the Event of Out-of-Limit and Out-of-Trend Results Procedures should define actions to be taken when OOL excursions or adverse trends occur, e.g. Raise an NCR, OOS Initiate an investigation including root cause analysis, QRM, review of unusual events Remedial actions e.g. additional cleaning and sanitation Follow-up monitoring routine or increased level Review impact of result on previously filled batches Verification of effectiveness of any actions taken Need to fill a process simulation batch Slide 16 PharmOut 2017
Qualification of Equipment Laboratory equipment e.g. incubators, active air samplers, plate counters, autoclaves should be appropriately qualified, timers Incubators should be monitored, ideally continuously with dataloggers or linked to a BMS. Procedures should define actions to be taken when there are excursions There should be schedules and records for calibration and preventative maintenance activities Slide 17 PharmOut 2017
Review and Analysis of Data Clause 6.9 Some kinds of data (e.g. test results, yields, environmental controls) should be recorded in a manner permitting trend evaluation. Any Out of Trend or Out of Specification data should be addressed and subject to investigation. Routine review and analysis of environmental monitoring data is essential to aid in the interpretation of process stability and assess overall control performance. Results should be trended and subject to management review (Clause 1.6) Slide 18 PharmOut 2017
Review and Analysis of Data Monitoring trend reports typically generated quarterly and/or yearly (minimum) Alert and Action limits should be reviewed as part of routine trend analysis. They may be revised to reflect improvements, advances in technology, changes in use patterns, or other changes Slide 19 PharmOut 2017
Operator (Gowning) Qualification Personnel required to work in an aseptic environment are required to be trained and certified to properly gown via a gowning certification process. Gowning certification may include additional monitoring sites beyond those routinely monitored e.g. the forehead, mask, neck, forearm, wrists, shoulders, finger impressions, chest, garment zipper. Acceptance criteria x3 consecutive satisfactory results Bi-annual or yearly gowning re-certification (x1) should occur. Slide 20 PharmOut 2017
Operator (Gowning) Qualification Action limits are generally based on any applicable regulatory requirements (Annex 1). Alert limits are driven by a review of historical data or commensurate with the activities being performed. Procedures should define actions to be taken if results exceed the Action level e.g. Retraining and/or recertification Restrict operator access to the aseptic filling room Slide 21 PharmOut 2017
Routine Personnel Monitoring Routine monitoring should include finger impressions from both hands e.g. Each time an operator exits a filling room After critical operations e.g. aseptic set up of the filling machine. After maintenance activities Consideration should also be given to monitoring garments e.g. chest, forearms and/or wrists, at a defined frequency Operators should be instructed not to sanitise their gloves immediately before prints are taken Slide 22 PharmOut 2017
Routine Personnel Monitoring Action limits are generally based on applicable regulatory requirements (Annex 1). For RABS, an Action limit of NMT 5cfu (Grade B) may be acceptable in operation however, different limits would be required for samples taken at the end of aseptic set up of the filling machine. Slide 23 PharmOut 2017
Identification of Isolates The manufacturer should have a system for the identification of microorganisms. This may be occur inhouse or by the use of external contract laboratories Automated methods are either phenotypic or genotypic methods. Identification by genotypic method is required is identification is required to invalidate a sterility test positive The frequency and level of identification should be defined in a procedure e.g. All microorganisms isolated from Grade A & B areas are speciated. All microorganisms isolated from Grade C & D areas identified to genus level Slide 24 PharmOut 2017
Non-sterile and Complementary Medicines For non-sterile and complementary medicines, the requirements for viable environmental monitoring are not as clear or defined. For these products, risk management principles should be used to determine the microbial quality of the environment commensurate with the products manufactured within Monitoring frequency typically every 3 or 6 months. Monitoring methods such as settle plates, volumetric air and surface sampling (e.g. swabs and contact plates) are acceptable Slide 25 PharmOut 2017
Non-sterile and Complementary Medicines Alert and Action limits must be defined. Should be based on historical data; typically based on Annex 1, Grade D limits Actions to be taken in the event of OOL excursions are often poorly defined e.g. Identification of microorganism isolated Cleaning and sanitation Follow up monitoring Trending of data is expected Slide 26 PharmOut 2017
Recap? There are regulations which mandate how an environmental monitoring program is designed The environmental monitoring program should be designed and implemented based on sound scientific principles. Regulatory inspectors are individuals with specific areas of interest and expectations Slide 27 PharmOut 2017
Thank you for your time. Questions? Tanja Varglien Lead Consultant tanja.varglien@pharmout.net Slide 28 PharmOut 2017
PharmOut Copyright Notice - 2017 All rights reserved This presentation and all associated materials are copyrighted and all rights reserved by PharmOut. No part of this presentation may be reproduced or transmitted in any form or for any purpose without the express permission of PharmOut in writing. The information contained herein may be changed without prior notice. Data contained in this presentation serves informational purposes only. PharmOut does not warrant the accuracy or completeness of the information, text, graphics, links, or other items contained within this presentation. This presentation is provided without a warranty of any kind, either express or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. PharmOut shall have no liability for damages of any kind including without limitation direct, special, indirect, or consequential damages that may result from the use of this presentation. Slide 29 PharmOut 2017